WWW.IJRPR.COM

**International Journal of Research Publication and Reviews**

Journal homepage: www.ijrpr.com ISSN 2582-7421

# Comparative Study of Anti-Hypertensive Drugs (Beta-Blockers)

***Rahul B. Jadhav[1], Deepali D. Wagh****

Department of Chemistry, Aditya Institute of Pharmacy, Chalisgaon
rahul1137jadhav@gmail.com
DOI : https://doi.org/10.55248/gengpi.6.0525.19115

**ABSTRACT**

Hypertension remains a leading risk factor for cardiovascular diseases globally. Beta-blockers have been a cornerstone in antihypertensive therapy. This study aims to compare the efficacy, safety, and pharmacological profiles of various beta-blockers, including first, second, and third generations, in the management of hypertension.

## Introduction

Hypertension (HT), a common condition especially prevalent after middle age, is not a disease in itself but serves as a significant contributor to cardiovascular disease and death. The threshold distinguishing normal from elevated blood pressure is somewhat arbitrary. In clinical practice, hypertension is generally defined as the level of blood pressure (BP) at which long-term treatment leads to a reduction in cardiovascular events and mortality. Most major guidelines—including NICE (2011), JNC8 (2014), WHO-ISH (2003), and the European Society of Hypertension (2007, 2013)—identify 140/90 mm Hg as the cut-off for diagnosis. However, JNC8 adjusted this to 150/90 mm Hg for those aged over 60. Studies consistently show that as blood pressure rises, so does the risk for cardiovascular complications.

The majority of hypertension cases are categorized as essential (or primary) hypertension, where no identifiable cause exists. Although overactivity of the sympathetic nervous system and the renin-angiotensin system (RAS) is not always present, these systems play key roles in regulating vascular tone and cardiac output in both normotensive and hypertensive individuals. Many antihypertensive agents target these pathways and, over time, can recalibrate the body's internal BP regulation mechanism to operate at a lower set point.

Treatment options for hypertension have vastly improved over the past six decades. In the era before 1950, few medications were both effective and tolerable. Agents like Veratrum and sodium cromate were available but posed significant toxicity risks. The 1950s saw the emergence of ganglion blockers, which worked well but were burdened with side effects. Reserpine was a notable advancement but had psychiatric side effects like depression. Hydralazine showed potential but caused problematic adverse effects when used alone. Guanethidine, introduced in 1961, represented an improvement in tolerability over earlier ganglion blockers. During the 1960s and 70s, medications like methyldopa, beta-blockers, thiazide and loop diuretics, and clonidine came into widespread use. By the 1970s, beta-blockers and diuretics were well-established, and prazosin, a selective alpha-blocker, expanded therapeutic options.

In the 1980s and 90s, the development of ACE inhibitors and calcium channel blockers significantly improved treatment efficacy. These were soon followed by angiotensin II receptor blockers (ARBs) like losartan, and more recently, direct renin inhibitors such as aliskiren. With this growing arsenal of medications, improved understanding of combination therapy, and long-term outcome data, hypertension can now be effectively managed in most patients with relatively few side effects. Clinical guidelines now provide evidence-based recommendations for drug selection tailored to specific patient profiles.

Hypertension affects approximately 1.13 billion people worldwide, with a significant burden in low- and middle-income countries. Beta-blockers, introduced in the 1960s, have been extensively used in treating hypertension. Their mechanisms involve blocking β-adrenergic receptors, leading to decreased heart rate and cardiac output, thereby reducing blood pressure.




atenolol




propanolol

**Classification of Beta-Blockers**

Beta-blockers are classified into three generations based on their pharmacological properties:

- **First Generation**: Non-selective β1 and β2 blockers (e.g., Propranolol, Nadolol)
- **Second Generation**: Cardioselective β1 blockers (e.g., Metoprolol, Atenolol)
- **Third Generation**: Non-selective β blockers with additional vasodilatory properties (e.g., Carvedilol, Nebivolol)

**Comparative Efficacy**

A meta-analysis of 26 randomized controlled trials involving 19,170 patients assessed the impact of beta-blockers on mortality in heart failure patients. The study found a significant reduction in all-cause mortality with beta-blocker use, irrespective of heart failure etiology.

Comparative studies between nebivolol and other antihypertensive agents revealed that nebivolol was associated with a higher risk of stroke compared to ACE inhibitors and thiazide diuretics.

**Introduction**

Atenolol and Propranolol are among the most widely prescribed beta-blockers, commonly used to treat cardiovascular issues such as high blood pressure, chest pain (angina), and arrhythmias. While both belong to the same drug class, they differ significantly in terms of their pharmacological actions, clinical indications, and potential side effects. This comparison reviews their characteristics across several domains, including pharmacology, clinical uses, effectiveness, side effects, and patient outcomes.

**Pharmacological Properties**

**1. Atenolol:**

- **Mode of Action:** Atenolol selectively targets β1-adrenergic receptors found mainly in the heart, reducing heart rate and contractility, thereby lowering blood pressure and controlling certain arrhythmias.
- **Pharmacokinetics:** It has a half-life of approximately 6–9 hours, making once-daily dosing possible. Since it is eliminated unchanged through the kidneys, it is suitable for patients with liver issues.
- **Bioavailability:** Oral absorption is about 50%, with peak levels occurring 2–4 hours after ingestion.

**2. Propranolol:**

- **Mode of Action:** Propranolol is a non-selective beta-blocker that inhibits both β1 and β2 receptors. This broader inhibition can cause bronchoconstriction, making it risky for people with asthma or COPD.
- **Pharmacokinetics:** It has a shorter half-life of 3–6 hours and undergoes extensive first-pass metabolism in the liver, reducing its bioavailability to 25–35%.
- **Bioavailability:** Its high lipid solubility enables it to cross the blood-brain barrier, which contributes to central nervous system (CNS) side effects like fatigue and sleep disturbances.

**Clinical Uses**

**Atenolol:**

- Effective in managing hypertension due to its selective action on heart receptors.
- Used to prevent angina by reducing the heart's oxygen demand.
- Helps manage both supraventricular and ventricular arrhythmias.
- Recommended post-myocardial infarction to lower the risk of further cardiac events.

**Propranolol:**

- Used for hypertension, especially when accompanied by conditions like migraines or anxiety.
- Helps control angina similar to Atenolol.
- Widely prescribed for migraine prevention.
- Commonly used to manage performance anxiety and essential tremors.

**Efficacy**

**Atenolol:**

- Effective at lowering blood pressure and controlling heart rate.
- Particularly useful in managing tachycardia and preventing complications post-MI.
- May be less effective than some other agents in reducing the recurrence of stroke.

**Propranolol:**

- Equally effective as Atenolol for hypertension, though often with more side effects.
- More versatile, especially for treating migraines and anxiety disorders.

**Adverse Effects**

**Atenolol:**

- Common side effects include tiredness, dizziness, slow heart rate, and low BP.
- Rare but serious issues include heart block, bronchospasm, and worsening of peripheral vascular disease.
- May obscure signs of low blood sugar, posing a concern for diabetic patients.

**Propranolol:**

- Shares many side effects with Atenolol but also causes bronchospasm due to β2 blockade.
- CNS-related side effects like insomnia and vivid dreams are more likely due to its ability to enter the brain.
- Can worsen Raynaud's phenomenon due to effects on peripheral circulation.

**Patient Outcomes**

**Atenolol:**

- Preferred for patients with heart-related conditions because of its selective action and safer profile for people with respiratory problems.
- Beneficial in cases of heart failure, angina, and after heart attacks.

**Propranolol:**

- Offers more diverse benefits, particularly for migraine prevention and anxiety, but carries a higher risk of side effects, especially for those with lung conditions or mood disorders.
- Demonstrates strong long-term results in managing non-cardiac conditions like migraines and tremors.

**Safety Profiles**

The safety profiles of beta-blockers vary:

- **Nebivolol**: Associated with a higher risk of bradycardia compared to ACE inhibitors and thiazide diuretics.
- **Atenolol**: Linked to a higher risk of vasculitis.
- **Carvedilol**: Demonstrated a lower risk of hospitalization for heart failure compared to metoprolol.

## Conclusion

While both Atenolol and Propranolol are effective beta-blockers, their differences make them suitable for different patient populations. Atenolol, being cardioselective, is better suited for individuals with heart conditions and those at risk for respiratory side effects. On the other hand, Propranolol's broad action makes it a valuable choice for treating conditions beyond the heart, such as migraines and anxiety, albeit with increased risk of side effects. Clinicians should assess each patient's overall health, coexisting conditions, and therapeutic needs to determine the most appropriate option.

## Comparative Summary

| Aspect | Atenolol | Propranolol |
|---|---|---|
| Lipophilicity | Hydrophilic | Lipophilic |
| Beta-1 Selectivity | High | Moderate |
| CNS Side Effects | Lower | Higher |
| Blood Pressure Control | Effective | Effective |
| Angina Management | Effective | Effective |
| Infantile Hemangiomas | Less effective, fewer side effects | More effective, more side effects |

**REFERENCE:**


1. Fauchier L, et al. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: A meta-analysis of randomised controlled trials. *Eur J Heart Fail*. 2007;9(6-7):614-621.
2. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients. *Hypertension*. 2020;75(5):1182-1192.
3. A meta-analysis of randomized controlled trials assessing the impact of beta-blockers on arterial stiffness, peripheral blood pressure and heart rate. *J Hypertens*. 2016;34(6):1091-1100.
4. ACE Inhibitors vs. Beta Blockers: How Are They Different? *Verywell Health*. 2024.
5. Long-Term Beta-Blocker Use May Not Benefit Certain Patients, Studies Find. *Verywell Health*. 2023.
6. Blood Pressure Drugs May Lower Risk of Depression. *Time*. 2016.
7. Hansson L, et al. *Effect of Angiotensin-Converting-Enzyme Inhibition Compared with Conventional Therapy on Mortality in Hypertension: The Captopril Prevention Project (CAPPP).Lancet.* 1999;353(9169):611–616.
8. Garg R, et al. *Effect of Metoprolol on Mortality and Morbidity in Patients with Left Ventricular Dysfunction After Acute Myocardial Infarction: A Randomized Controlled Trial. JAMA.* 1996;275(14):1017–1022.
9. Packer M, et al. *Carvedilol and Survival in Severe Chronic Heart Failure.* *N Engl J Med.* 2001;344(22):1651–1658.
10. Krum H, et al. *Nebivolol versus Metoprolol in Patients with Chronic Heart Failure: A Randomized, Double-Blind, Parallel-Group Study.Lancet.* 2009;374(9695):119–126.
11. Gheorghiade M, et al. *Efficacy and Safety of Bisoprolol in Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Cardiol.* 2003;91(2):139–144.
12. Pfeffer MA, et al. *Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fraction and Congestive Heart Failure. N Engl J Med.* 1992;327(10):685–691.
13. Poole-Wilson PA, et al. *Comparison of Carvedilol and Metoprolol in Patients with Chronic Heart Failure: A Randomized, Double-Blind, Parallel-Group Study.* *Lancet.* 2003;362(9377):7–13.
14. Ostergren J, et al. *Nebivolol Versus Metoprolol in Hypertension: A Randomized, Double-Blind, Parallel-Group Study.J Hypertens.* 2005;23(3):587–594.
15. Lindholm LH, et al. *Beta-Blockers in Hypertension: A Meta-Analysis of Randomized Controlled Trials.Lancet.* 2005;366(9496):1349–1359.
16. Bangalore S, et al. *Risk of Diabetes with Beta-Blocker Therapy: A Meta-Analysis.* *JAMA.* 2007;298(24):2743–2751.
17. Packer M, et al. *Carvedilol and Survival in Severe Chronic Heart Failure.* *N Engl J Med.* 2001;344(22):1651–1658.
18. Garg R, et al. *Effect of Metoprolol on Mortality and Morbidity in Patients with Left Ventricular Dysfunction After Acute Myocardial Infarction: A Randomized Controlled Trial. JAMA.* 1996;275(14):1017–1022.
19. Gheorghiade M, et al. *Efficacy and Safety of Bisoprolol in Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Cardiol.* 2003;91(2):139–144.
20. Pfeffer MA, et al. *Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fraction and Congestive Heart Failure. N Engl J Med.* 1992;327(10):685–691.
21. Poole-Wilson PA, et al. *Comparison of Carvedilol and Metoprolol in Patients with Chronic Heart Failure: A Randomized, Double-Blind, Parallel-Group Study.* *Lancet.* 2003;362(9377):7–13.
22. Ostergren J, et al. *Nebivolol Versus Metoprolol in Hypertension: A Randomized, Double-Blind, Parallel-Group Study.J Hypertens.* 2005;23(3):587–594.
23. Lindholm LH, et al. *Beta-Blockers in Hypertension: A Meta-Analysis of Randomized Controlled Trials.Lancet.* 2005;366(9496):1349–1359.
24. Bangalore S, et al. *Risk of Diabetes with Beta-Blocker Therapy: A Meta-Analysis.* *JAMA.* 2007;298(24):2743–2751.

**25.** Bangalore S, et al. *Beta-Blockers and Risk of Depression: A Meta-Analysis. J Clin Psychiatry.* 200